• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immatics N.V. - Ordinary Shares (NQ:IMTX)

    9.680 -0.510 (-5.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 802,620
    Open 10.02
    Bid (Size) 5.700 (400)
    Ask (Size) 9.940 (2,200)
    Prev. Close 10.19
    Today's Range 9.500 - 10.34
    52wk Range 3.300 - 11.25
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
    Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
    Via MarketMinute
    Topics Initial Public Offering Regulatory Compliance Workforce
    Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
    From https://immatics.com/
    Via GlobeNewswire

    Performance

    YTD
    +30.5%
    +30.5%
    1 Month
    +3.0%
    +3.0%
    3 Month
    +46.4%
    +46.4%
    6 Month
    +89.8%
    +89.8%
    1 Year
    +3.5%
    +3.5%

    More News

    Read More
    Immatics Appoints Venkat Ramanan as Chief Financial Officer
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Appoints Amie Krause as Chief People Officer
    From https://immatics.com/
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Immatics Announces Second Quarter 2025 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces First Quarter 2025 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces Full Year 2024 Financial Results and Business Update
    From https://immatics.com/
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces Pricing of $150 Million Public Offering
    From https://immatics.com/
    Via GlobeNewswire
    Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Immatics Announces Proposed $150 Million Public Offering
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
    From https://immatics.com/
    Via GlobeNewswire
    Biotech Stocks : Are You A Trader Or A Longer Term Investor?
    Via Talk Markets
    Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
    From https://immatics.com/
    Via GlobeNewswire
    Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
    From https://immatics.com/
    Via GlobeNewswire
    IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace

    Frequently Asked Questions

    Is Immatics N.V. - Ordinary Shares publicly traded?
    Yes, Immatics N.V. - Ordinary Shares is publicly traded.
    What exchange does Immatics N.V. - Ordinary Shares trade on?
    Immatics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Immatics N.V. - Ordinary Shares?
    The ticker symbol for Immatics N.V. - Ordinary Shares is IMTX on the Nasdaq Stock Market
    What is the current price of Immatics N.V. - Ordinary Shares?
    The current price of Immatics N.V. - Ordinary Shares is 9.680
    When was Immatics N.V. - Ordinary Shares last traded?
    The last trade of Immatics N.V. - Ordinary Shares was at 11/03/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.